Credit Suisse raised their price target on shares of St. Jude Medical (NYSE: STJ) from $48.00 to $51.00 in a research note issued on Tuesday, StockRatingsNetwork.com reports. The firm currently has an “outperform” rating on the stock. Credit Suisse’s price target points to a potential upside of 5.24% from the company’s current price.
A number of other firms have also recently commented on STJ. Analysts at TheStreet reiterated a “buy” rating on shares of St. Jude Medical in a research note to investors on Tuesday, July 9th.
Four analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $45.26.
St. Jude Medical (NYSE: STJ) traded down 0.88% on Tuesday, hitting $48.46. St. Jude Medical has a 1-year low of $30.25 and a 1-year high of $48.91. The stock’s 50-day moving average is currently $45.19. The company has a market cap of $13.732 billion and a price-to-earnings ratio of 19.67.
St. Jude Medical (NYSE: STJ) last announced its earnings results on Wednesday, April 17th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.91 by $0.01. The company had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the previous year, the company posted $0.86 earnings per share. The company’s revenue for the quarter was down 4.1% on a year-over-year basis. St. Jude Medical has set its Q2 guidance at $0.93-0.95 EPS and its FY13 guidance at $3.68-3.73 EPS. Analysts expect that St. Jude Medical will post $3.69 EPS for the current fiscal year.
St. Jude Medical, Inc (NYSE: STJ) develops, manufactures and distributes cardiovascular medical devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.